Neuraminidase is one of the targets of influenza therapeutic drugs. Since humans understand the role of this enzyme, research on this enzyme inhibitor has begun. Currently, two neuraminidase inhibitors have been marketed. Entered Phase III clinical study.
The neuraminidase inhibitors currently under investigation can be classified into six categories according to their structures: sialic acid analogs, benzoic acid derivatives, cyclohexene derivatives, cyclopentane derivatives, pyrrolidine derivatives, and natural extracts. These four major inhibitors act as conserved sequences at the center of the neuraminidase barrel structure. There is a cyclic central structure in the molecular structure. The structure-activity relationship study shows that the size and saturation of the ring structure have little effect on the activity of the inhibitor. The configuration and electrical properties of the substituents on the ring are the key to determine the activity of the inhibitor. nature.
Neuraminidase inhibitors currently on the market include zanamivir of GlaxoSmithKline and oseltamivir of Roche.
Neuraminidase as an inhibitor
